Ligand Pharmaceuticals Incorporated (LGND) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Jupiter, CA, アメリカ. 現CEOは Todd C. Davis.
LGND を有する IPO日 1992-11-18, 68 名の正社員, に上場 NASDAQ Global Market, 時価総額 $4.63B.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and acquires innovative technologies to enable pharmaceutical companies to discover and develop medicines globally. The company maintains a diverse commercial portfolio spanning oncology, infectious disease, endocrinology, and other therapeutic areas, with key marketed products including Kyprolis and Evomela for multiple myeloma, Veklury for COVID-19, Vaxneuvance for pneumococcal disease prevention, and Zulresso for postpartum depression, among numerous others. Beyond its marketed medications, Ligand operates an extensive pipeline of partner and licensed programs in clinical development targeting cancer, seizure disorders, diabetes, cardiovascular disease, and other conditions. The company also supplies Captisol materials, a proprietary technology platform used in pharmaceutical formulations. Founded in 1987 and headquartered in Emeryville, California, Ligand serves as a strategic partner to the global pharmaceutical industry.
